Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Mar 22;11:2339–2348. doi: 10.2147/CMAR.S177623

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 Ye et al. This work is published and licensed by Dove Medical Press Limited

The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.

PMC Copyright notice

UNBS5162 and amonafide inhibit the activation of the AKT/mTOR pathway and reverse the epithelial–mesenchymal transition process in human melanoma cells. (A–D) Western blot was performed to confirm the pathway by which UNBS5162 and amonafide inhibited tumor progression; phosphorylation of AKT and mTOR were inhibited in M14 and A375 cells treated with 10 µM UNBS5162 or 8 µM amonafide for 48 hours, as well as P70/S6K and Cyclin D1. (C–H) The expressions of N-cad, Snail, Vimentin, and slug in UNBS5162 and amonafide groups decreased significantly, whereas E-cad increased significantly.

Note: *P<0.05.

Abbreviation: NC, negative control.